Resultados da pesquisa - Atsuko Ogino

  • A mostrar 1 - 9 resultados de 9
Refinar resultados
  1. 1
    Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation <i>In vivo</i>

    Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation <i>In vivo</i> Por Eiki Ichihara, Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Atsuko Ogino, Mitsune Tanimoto, Katsuyuki Kiura

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  2. 2
    Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line

    Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line Por Atsuko Ogino, Hiroyuki Kitao, Seiki Hirano, Akiko Uchida, Masamichi Ishiai, Toshiyuki Kozuki, Nagio Takigawa, Minoru Takata, Katsuyuki Kiura, Mitsune Tanimoto

    Publicado em 2007
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  3. 3
    Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Non–Small Cell Lung Cancer

    Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Non–Small Cell Lung Cancer Por Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y. Yeap, Lynette M. Sholl, Bruce E. Johnson, Pasi A. Jänne

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer

    Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer Por Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

    Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors Por Takayuki Kosaka, Junko Tanizaki, Raymond M. Paranal, Hideki Endoh, Christine Lydon, Marzia Capelletti, Claire E. Repellin, Jihyun Choi, Atsuko Ogino, Antonio Calles, Dalia Ercan, Amanda J. Redig, Magda Bahcall, Geoffrey R. Oxnard, Michael J. Eck, Pasi A. Jänne

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

    A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors Por Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher S. Lathan, Judith Marcoux, Jinyan Du, Katsuhiro Okuda, Marzia Capelletti, Takeshi Shimamura, Dalia Ercan, Magda Stumpfova, Yun Xiao, Stanislawa Weremowicz, Mohit Butaney, Stéphanie Héon, Keith D. Wilner, James G. Christensen, Michel J. Eck, Kwok‐Kin Wong, Neal I. Lindeman, Nathanael S. Gray, Scott J. Rodig, Pasi A. Jänne

    Publicado em 2011
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

    An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer Por Ciric To, Tyler S. Beyett, Jaebong Jang, William W. Feng, Magda Bahcall, Heidi M. Haikala, Bo Hee Shin, David E. Heppner, Jaimin K. Rana, Brittaney A. Leeper, Kara M. Soroko, Michael J. Poitras, Prafulla C. Gokhale, Yoshihisa Kobayashi, Kamal Wahid, Kari J. Kurppa, Thomas W. Gero, Michael D. Cameron, Atsuko Ogino, Mierzhati Mushajiang, Chunxiao Xu, Yanxi Zhang, David A. Scott, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne

    Publicado em 2022
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment

    Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment Por Bassel Alsaed, Linh Lin, Jieun Son, Jiaqi Li, Johannes Smolander, Timothy Lopez, Pınar Ö. Eser, Atsuko Ogino, Chiara Ambrogio, Yoonji Eum, Tran C. Thai, Haiyun Wang, Eva Sutinen, Hilma Mutanen, Hanna Duàn, Nina Bobik, Kristian Borenius, William W. Feng, Behnam Nabet, Satu Mustjoki, Sanna Laaksonen, Benjamin K. Eschle, Michael J. Poitras, David A. Barbie, Ilkka Ilonen, Prafulla C. Gokhale, Pasi A. Jänne, Heidi M. Haikala

    Publicado em 2025
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

    MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer Por Shunsuke Kitajima, Tetsuo Tani, Benjamin F. Springer, Marco Campisi, Tatsuya Osaki, Koji Haratani, Minyue Chen, Erik H. Knelson, Navin R. Mahadevan, Jessica Ritter, Ryohei Yoshida, Jens Köhler, Atsuko Ogino, Ryu‐Suke Nozawa, Shriram K. Sundararaman, Tran C. Thai, Mizuki Homme, Brandon Piel, Sophie Kivlehan, Bonje Obua, Connor Purcell, Mamiko Yajima, Thanh U. Barbie, Patrick H. Lizotte, Pasi A. Jänne, Cloud P. Paweletz, Prafulla C. Gokhale, David A. Barbie

    Publicado em 2022
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: